Dihydrofolate reductase · SINGLE PROTEIN · Pneumocystis carinii
This target will appear in recent viewed items on this browser. Use the demo workspace to preview watch rules and decision queues.
Move to another high-traffic target or paste a specific ChEMBL target ID.
Structured disease, protein, and project context should read before the lower-level identity rail.
As of 2026-09-14Dihydrofolate reductase shows late clinical disease relevance led by pneumocystosis. 3 more disease programs remain visible in the same review block. 1 linked drug keeps the current disease frame grounded. Protein identity stays anchored to UniProt P16184. Start with pneumocystosis, then reuse UniProt P16184 as the stable protein anchor across project notes and exports.
Start with pneumocystosis, then reuse UniProt P16184 as the stable protein anchor across project notes and exports.
Dihydrofolate reductase shows late clinical disease relevance led by pneumocystosis. 3 more disease programs remain visible in the same review block. 1 linked drug remains visible in the same block.
Start review with pneumocystosis because it currently carries late clinical support. Linked drugs include TRIMETREXATE GLUCURONATE. This disease block keeps the Open Targets-ready contract explicit while current evidence comes from ChEMBL mechanism and indication mappings.
Disease source · ChEMBL drug mechanism + indication proxyDihydrofolate reductase
Review this target as Dihydrofolate reductase, mapped to UniProt P16184. Sequence length is 206 aa.
Protein source · UniProt accession via ChEMBL component mappingKeep the review anchor, source IDs, and context contract aligned before reusing this target elsewhere.
This review treats Dihydrofolate reductase as ChEMBL target CHEMBL1926, mapped to UniProt P16184. Disease framing currently uses the Open Targets-ready proxy contract.
Reuse the same identifiers in notes, watch rules, exports, and review packs so provenance stays stable across surfaces.
Choose the first block or source based on the question you are trying to answer.
Start here when your first question is whether Dihydrofolate reductase is the right protein anchor across sources, using UniProt P16184 as the stable mapping.
Jump to Protein ContextUse this block first when you need to confirm why pneumocystosis is currently framed as late clinical support. It currently carries 1 linked drug in the same disease frame.
Jump to Disease ContextOpen the one-page evidence card when you want the rationale, activity base, and attribution together.
Open Review-ready CardVerify identity, organism, and the fastest next research jumps from the same page.
| Preferred Name | Dihydrofolate reductase |
| Target Type | SINGLE PROTEIN |
| Organism | Pneumocystis carinii |
| UniProt | P16184 |
Reviewable protein naming and mapping context for this target snapshot.
| Protein Label | Dihydrofolate reductase |
| UniProt Accession | P16184 |
| Component Type | Protein |
| Sequence Length | 206 aa |
Dihydrofolate reductase
Review this target as Dihydrofolate reductase, mapped to UniProt P16184. Sequence length is 206 aa.
Open Targets-ready disease context using the current target-indication evidence contract.
Dihydrofolate reductase shows late clinical disease relevance led by pneumocystosis. 3 more disease programs remain visible in the same review block.
Start review with pneumocystosis because it currently carries late clinical support. Linked drugs include TRIMETREXATE GLUCURONATE. This disease block keeps the Open Targets-ready contract explicit while current evidence comes from ChEMBL mechanism and indication mappings.
| ChEMBL ID | pChEMBL | Type | Value (nM) | Phase |
|---|---|---|---|---|
| CHEMBL190650 | 10.01 | IC50 | 0.097 | Preclinical |
| CHEMBL7492 | 9.85 | Ki | 0.143 | Clinical |
| CHEMBL190486 | 9.77 | IC50 | 0.17 | Preclinical |
| CHEMBL145979 | 9.59 | Ki | 0.26 | Preclinical |
| CHEMBL189952 | 9.37 | IC50 | 0.43 | Preclinical |
| CHEMBL190199 | 9.29 | IC50 | 0.51 | Preclinical |
| CHEMBL370239 | 9.19 | IC50 | 0.65 | Preclinical |
| CHEMBL119 | 9.15 | Ki | 0.71 | Approved |
| CHEMBL300419 | 9.0 | IC50 | 1.0 | Preclinical |
| CHEMBL34259 | 9.0 | IC50 | 1.0 | Approved |
| BAO Format | Assays | Compounds | Avg pChEMBL |
|---|---|---|---|
| single protein format | 98 | 624 | 6.2 |
| assay format | 2 | 1 | 8.9 |
| BAO Format | Assays | Compounds | Avg pChEMBL |
|---|---|---|---|
| assay format | 1 | 1 | 7.5 |